Open AccessNewer HMG‐CoA reductase inhibitor (statin) therapies
Author(s) -
Brinton Eliot A.
Publication year - 2001
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960240705
Subject(s) - medicine , statin , hmg coa reductase , triglyceride , cholesterol , national cholesterol education program , reductase , ldl cholesterol , hydroxymethylglutaryl coa reductase inhibitors , pharmacology , low density lipoprotein , lipoprotein , endocrinology , enzyme , biochemistry , metabolic syndrome , obesity , chemistry
Although most patients can achieve their National Cholesterol Education Program goal with a reduction of ≤30% in low‐density lipoprotein cholesterol (LDL‐C) levels available with all statins, some patients need greater LDL‐C lowering. Furthermore, new study data suggest that greater clinical event reduction may be obtained with more aggressive LDL‐C lowering and/or with treatment of factors beyond LDL‐C. New formulations of statins, including extended‐release preparations, are achieving greater reductions in LDL‐C levels as well as favorable modification of high‐density lipoprotein cholesterol and triglyceride concentrations while maintaining an excellent safety profile.